Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Mar;16(5):293-308.
doi: 10.2217/epi-2023-0339. Epub 2024 Feb 15.

Alteration of DNA methyltransferases by eribulin elicits broad DNA methylation changes with potential therapeutic implications for triple-negative breast cancer

Meisam Bagheri  1   2 , Min Kyung Lee  3 , Kristen E Muller  2   4 , Todd W Miller  1   2   5   6 , Diwakar R Pattabiraman  1   2 , Brock C Christensen  1   3   7
Affiliations

Alteration of DNA methyltransferases by eribulin elicits broad DNA methylation changes with potential therapeutic implications for triple-negative breast cancer

Meisam Bagheri et al. Epigenomics. 2024 Mar.

Abstract

Background: Triple-negative breast cancer (TNBC) is an aggressive disease with limited treatment options. Eribulin, a chemotherapeutic drug, induces epigenetic changes in cancer cells, suggesting a unique mechanism of action. Materials & methods: MDA-MB 231 cells were treated with eribulin and paclitaxel, and the samples from 53 patients treated with neoadjuvant eribulin were compared with those from 14 patients who received the standard-of-care treatment using immunohistochemistry. Results: Eribulin treatment caused significant DNA methylation changes in drug-tolerant persister TNBC cells, and it also elicited changes in the expression levels of epigenetic modifiers (DNMT1, TET1, DNMT3A/B) in vitro and in primary TNBC tumors. Conclusion: These findings provide new insights into eribulin's mechanism of action and potential biomarkers for predicting TNBC treatment response.

Keywords: DNA methylation; breast cancer; chemotherapy; epigenetic; epithelial-to-mesenchymal transition.

PubMed Disclaimer

Conflict of interest statement

Competing interests disclosure

This study was partially supported by Eisai Inc. through a Sponsored Research Agreement, which was reviewed and approved by Eisai Inc. The authors and Eisai Inc. declare no competing interests related to the study. The authors have no other competing interests or relevant affiliations with any organization or entity with the subject matter or materials discussed in the manuscript apart from those disclosed. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

Figures

Figure 1.
Figure 1.. Eribulin treatment alters DNA methylation patterns in triple-negative breast cancer cells.
(A & B) Schematic and brightfield representation of multi-round drug treatment procedure that resulted in the generation of resistant clones. (C) Principal component analysis of the most variable genes between MDA MB-231 parental, ERI1, ERI2, PAC1 and PAC2 from DNA methylation array. (D) Heat map of unsupervised hierarchical clustering of methylation β-values of the top 5% most variable CpGs (34,525 CpGs). Horizontal tracking bars indicate the treatment status. (E) Methylation dysregulation index of eribulin-treated and paclitaxel-treated cells at each treatment point. ERI: Eribulin; MDI: Methylation dysregulation index; PAC: Paclitaxel.
Figure 2.
Figure 2.. Additional eribulin treatment increases alterations in DNA methylation patterns.
(A) Volcano plot of dmCpGs associated with first eribulin treatment compared with the methylation status of parental cells determined by an epigenome-wide association study. (B) Volcano plots of dmCpGs associated with second eribulin treatment compared with the methylation status of parental cells determined by an epigenome-wide association study. Those colored in red are considered to be differentially methylated at a q-value < 0.05. (C) Comparison of number of dmCpGs based on treatment type and number of treatments. Those colored in red are the number of hypomethylated CpGs compared with the methylation status of parental cells. Colored in blue are the number of hypermethylated CpGs compared with methylation status of parental cells. (D) Venn diagram of dmCpGs associated with the first treatment of eribulin and associated with the second treatment of eribulin. (E) Number of genes that have either decreased, unchanged, or increased proportion of CpGs that are differentially methylated with the second treatment of eribulin as compared with the proportion of CpGs that are differentially methylated with the first treatment of eribulin. dmCpG: Differentially methylated CpG.
Figure 3.
Figure 3.. Eribulin treatment associated with differentially methylated CpGs are enriched.
Enrichment of differentially methylated CpG sites (dmCpGs) in various genomic contexts: (A) according to gene structure and (B) in association with CpG islands. Odds ratios were calculated by Fisher’s exact test. Blue points and confidence intervals indicate enrichment from dmCpGs associated with the first eribulin treatment. Yellow points and confidence intervals indicate enrichment from dmCpGs associated with the second eribulin treatment. Circular points indicate CpGs with increased methylation levels in treated cells. Triangular points indicate CpGs with decreased methylation levels in treated cells.
Figure 4.
Figure 4.. Differential methylation patterns are detected in mesenchymal-to-epithelial transition-associated genes.
(A & B) RT-PCR and immunoblot analysis of epithelial-to-mesenchymal transition markers in cells treated with eribulin and paclitaxel. (C) Heat map of the direction of methylation level change (β coefficient from epigenome-wide association study) in CpGs located in mesenchymal-to-epithelial transition (MET)-associated genes. Tiles with * indicate a significant difference in methylation levels compared with untreated cells. The vertical tracking bar indicates which MET-associated gene the CpG is located in. (D) Proportion of dmCpGs in different genomic regions of MET-associated genes by direction of methylation change and number of eribulin treatments. (E) Heat map of the level of significance for transcription factor motifs associated with dmCpGs in ZEB1 binding sites. *p < 0.05; **p < 0.001; ***p < 0.0005; ****p < 0.0001; t-test.
Figure 5.
Figure 5.. Genes with differentially methylated CpGs are associated with key biological processes in the mesenchymal-to-epithelial transition.
(A) The VEGF signaling pathway was associated with hypermethylated CpGs from the second eribulin treatment. (B) RT-PCR analysis was conducted on genes within pathways that were differentially methylated. (C–E) ZEB1 localization at genomic loci genes was evaluated by CUT&RUN signal track analysis across all conditions. (F) Heat map depicting the levels of cytokines and chemokines determined through a multiplex cytokine assay. *p < 0.05; **p < 0.001; ***p < 0.0005; ****p < 0.0001; t-test.
Figure 6.
Figure 6.. Eribulin treatment in primary human triple-negative breast cancers alters the expression of DNA methylation regulatory enzymes.
(A) Quantitative RT-PCR was performed to assess the expression levels of DNA methylation markers in the MDA MB-231 parental line and its resistant counterparts. (B) Immunoblotting was performed to assess the protein levels of DNA methylation markers in the MDA MB-231 parental line and its resistant counterparts. (C & D) Representative images and quantification of DNMT1 and DNMT3A were obtained through immunohistochemical analysis of specimens treated with AC-T and ERI. Statistical analysis was conducted using the t-test. AC-T: Adriamycin/cyclophosphamide followed by paclitaxel; ERI: Eribulin.
See this image and copyright information in PMC

Update of

References

    1. Nguyen HT, Huynh LAK, Nguyen TV et al. Multimodal analysis of ctDNA methylation and fragmentomic profiles enhances detection of nonmetastatic colorectal cancer. Future Oncol. 18(35), 3895–3912 (2022). - PubMed
    1. Lehmann BD, Bauer JA, Chen X et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J. Clin. Invest. 121(7), 2750–67 (2011). - PMC - PubMed
    1. Foulkes WD, Smith IE, Reis-Filho JS. Triple-negative breast cancer. N. Engl. J. Med. 363(20), 1938–48 (2010). - PubMed
    1. Houvenaeghel G, Sabatier R, Reyal F, Classe JM et al. Axillary lymph node micrometastases decrease triple-negative early breast cancer survival. Br. J. Cancer 115(9), 1024–1031 (2016). - PMC - PubMed
    1. Wang N, Ma T, Yu B. Targeting epigenetic regulators to overcome drug resistance in cancers. Sig. Transduct. Target Ther. 8, 69 (2023). - PMC - PubMed

    2. • Understanding epigenetic regulation in tumor resistance is crucial because it offers new avenues for cancer treatment, particularly in overcoming drug resistance, a major hurdle in effective cancer therapy.

MeSH terms